Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immatics N.V.    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
10.5(c) 10.69(c) 10.25(c) 10.26(c) 10.28(c) Last
132 546 121 440 75 734 55 806 19 701 Volume
+0.38% +1.81% -4.12% +0.10% +0.19% Change
More quotes
Financials (USD)
Sales 2020 34,1 M - -
Net income 2020 -78,1 M - -
Net cash position 2020 315 M - -
P/E ratio 2020 -7,37x
Yield 2020 -
Sales 2021 36,0 M - -
Net income 2021 -85,2 M - -
Net cash position 2021 232 M - -
P/E ratio 2021 -8,48x
Yield 2021 -
Capitalization 645 M 645 M -
EV / Sales 2020 9,69x
EV / Sales 2021 11,5x
Nbr of Employees 220
Free-Float 80,0%
More Financials
Company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT)... 
More about the company
All news about IMMATICS N.V.
11/16IMMATICS N : Factsheet English
PU
11/10IMMATICS N : ACTolog® IMA101 Phase-1-Data at the 35th Annual SITC conference
PU
11/10Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 ..
GL
11/02IMMATICS N : TCER IMA401 Preclinical Data Presentation at European Antibody Cong..
PU
10/29Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Progr..
GL
09/29IMMATICS N : Corporate Presentation, October 2020
PU
09/29Immatics Appoints Arnd Christ as Chief Financial Officer
GL
09/15Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
GL
09/14IMMATICS N : ACTengine® IMA204 Preclinical Data Update at HW CAR-TCR Digitial We..
PU
09/10Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting..
GL
09/03Immatics Announces Second Quarter 2020 Financial Results and Business Update
GL
08/18Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy P..
GL
08/06Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
GL
07/20IMMATICS N : Corporate Presentation
PU
07/20IMMATICS N : Registration of certain classes of securities 12(b) of the Securiti..
PU
More news
News in other languages on IMMATICS N.V.
11/16IMMATICS N : Factsheet German
More news
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 18,00 $
Last Close Price 10,28 $
Spread / Highest target 172%
Spread / Average Target 75,1%
Spread / Lowest Target 26,5%
EPS Revisions
Managers
NameTitle
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Peter Alan Chambré Chairman-Supervisory Board
Arnd Christ Chief Financial Officer
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMATICS N.V.0.00%645
LONZA GROUP AG55.15%44 901
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 811
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832